PMID- 34290981
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210723
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - HOTTIP Enhances Gemcitabine and Cisplatin Resistance Through Sponging miR-637 in 
      Cholangiocarcinoma.
PG  - 664916
LID - 10.3389/fonc.2021.664916 [doi]
LID - 664916
AB  - Chemo-resistance prominently hampers the effects of systemic chemotherapy to 
      cholangiocarcinoma (CCA). Long non-coding RNAs (lncRNAs) have been shown to have 
      great importance not only in tumorigenesis but also in therapeutic prognosis. The 
      aim of this study is to investigate the role of lncRNA HOTTIP in the 
      chemo-resistance to cisplatin and gemcitabine (CG) in CCA. The upregulated 
      expression of HOTTIP was observed in CCA patients and the upregulation was 
      associated with therapeutic responsiveness and prognosis. HOTTIP silencing 
      powerfully increased the chemotherapy sensitivity through weakening proliferation 
      and colony formation and increasing apoptosis. Subsequently, miR-637 was 
      identified as the functional target of HOTTIP, since mechanically it could be 
      targeted by HOTTIP and functionally its overexpression dismissed the changes by 
      HOTTIP silencing in vitro and in vivo. Moreover, LIM and SH3 domain protein 1 
      (LASP1) could be targeted and regulated by miR-637. In all, HOTTIP modulates the 
      sensitivity to CG in CCA through the HOTTIP/miR-637/LASP1 regulatory axis, 
      providing a new opportunities for CCA treatment.
CI  - Copyright (c) 2021 Gao, Chen and Yang.
FAU - Gao, Kun
AU  - Gao K
AD  - Department of Interventional Radiology, Beijing Chao-yang Hospital Affiliated 
      with Capital Medical University, Beijing, China.
FAU - Chen, Shuhua
AU  - Chen S
AD  - Department of Clinical Laboratory, Yunfu People's Hospital, Yunfu, China.
FAU - Yang, Xiangyu
AU  - Yang X
AD  - Department of Interventional Radiology, Beijing Chao-yang Hospital Affiliated 
      with Capital Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20210705
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8287300
OTO - NOTNLM
OT  - HOTTIP
OT  - LASP1
OT  - cholangiocarcinoma
OT  - long non-coding RNAs
OT  - miR-637
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/07/23 06:00
MHDA- 2021/07/23 06:01
PMCR- 2021/01/01
CRDT- 2021/07/22 06:35
PHST- 2021/02/10 00:00 [received]
PHST- 2021/06/16 00:00 [accepted]
PHST- 2021/07/22 06:35 [entrez]
PHST- 2021/07/23 06:00 [pubmed]
PHST- 2021/07/23 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.664916 [doi]
PST - epublish
SO  - Front Oncol. 2021 Jul 5;11:664916. doi: 10.3389/fonc.2021.664916. eCollection 
      2021.